Results of a randomized, double ‐blind, active‐controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder

ConclusionsPropiverine ER 30 mg was confirmed to be an effective and well‐tolerated treatment option for patients with OAB symptoms. This first head‐to‐head study showed non‐inferiority of propiverine ER 30 mg compared with tolterodine ER 4 mg.
Source: BJU International - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research

Related Links:

CONCLUSION: LACS allowed the anatomical reconstruction of the pelvic floor and proved to be a minimally invasive, fast, effective, safe and reproducible technique. More series are needed to evaluate its role against laparoscopic colposacropexy. PMID: 33032847 [PubMed - as supplied by publisher]
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Authors: Tags: Actas Urol Esp Source Type: research
Conclusions Three-dimensional ultrasound urodynamics can be used to identify differences in bladder shape comparing individuals with and without OAB. This method may be used to identify a subset of OAB patients with abnormal bladder shapes which may play a role in the pathophysiology of their OAB symptoms.
Source: Female Pelvic Medicine and Reconstructive Surgery - Category: OBGYN Tags: Original Articles Source Type: research
Conclusions Choline levels are significantly decreased in women complaining of OAB with urgency incontinence, and lower levels are associated with higher MESA scores.
Source: Female Pelvic Medicine and Reconstructive Surgery - Category: OBGYN Tags: Original Articles Source Type: research
Conditions:   Urge Incontinence;   Overactive Bladder (OAB) Intervention:   Drug: mirabegron Sponsor:   Astellas Pharma China, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Urge Incontinence;   Overactive Bladder (OAB) Intervention:   Drug: mirabegron Sponsor:   Astellas Pharma China, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Urge Incontinence;   Overactive Bladder (OAB) Intervention:   Drug: mirabegron Sponsor:   Astellas Pharma China, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Urge Incontinence;   Overactive Bladder (OAB) Intervention:   Drug: mirabegron Sponsor:   Astellas Pharma China, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Urge Incontinence;   Overactive Bladder (OAB) Intervention:   Drug: mirabegron Sponsor:   Astellas Pharma China, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Urge Incontinence;   Overactive Bladder (OAB) Intervention:   Drug: mirabegron Sponsor:   Astellas Pharma China, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Urge Incontinence;   Overactive Bladder (OAB) Intervention:   Drug: mirabegron Sponsor:   Astellas Pharma China, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Clinical Trials | Detrol | Drugs & Pharmacology | Electrocardiogram | Incontinence | Laboratory Medicine | Overactive Bladder | Overactive Bladder Syndrome | Study | Urology & Nephrology